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Abstract 
Aims: Myocardial infarction leads to an enhanced release of endocannabinoids and a massive 
accumulation of neutrophils and monocytes within the ischemic myocardium. These myeloid 
cells originate from hematopoietic precursors in the bone marrow and are rapidly mobilized in 
response to myocardial infarction. We aimed to determine whether endocannabinoid signaling 
is involved in myeloid cell mobilization and cardiac recruitment after ischemia onset. 
Methods and results: Intravenous administration of endocannabinoid 2-arachidonoylglycerol 
into wildtype C57BL6 mice induced a rapid increase of blood neutrophil and monocyte counts 
as measured by flow cytometry. This effect was blunted when using cannabinoid receptor 2 
knockout mice. In response to myocardial infarction induced in wildtype mice, the lipidomic 
analysis revealed significantly elevated plasma and cardiac levels of the endocannabinoid 2-
arachidonoylglycerol 24 h after infarction, but no changes in anandamide, 
palmitoylethanolamide and oleoylethanolamide. This was a consequence of an increased 
expression of 2-arachidonoylglycerol synthesizing enzyme diacylglycerol lipase and a decrease 
of metabolizing enzyme monoacylglycerol lipase in infarcted hearts, as determined by 
quantitative RT-PCR analysis. The opposite mRNA expression pattern was observed in bone 
marrow. Pharmacological blockade of monoacylglycerol lipase with JZL184 and thus increased 
systemic 2-arachidonoylglycerol levels in wildtype mice subjected to myocardial infarction 
resulted in elevated cardiac CXCL1, CXCL2 and MMP9 protein levels as well as higher cardiac 
neutrophil and monocyte counts 24 h after infarction compared to vehicle-treated mice. 
Increased post-myocardial infarction inflammation in these mice led to an increased infarct size, 
an impaired ventricular scar formation assessed by histology and a worsened cardiac function 
in echocardiography evaluations up to 21 days. Likewise, JZL184-administration in a 
myocardial ischemia-reperfusion model increased cardiac myeloid cell recruitment and resulted 
in a larger fibrotic scar size. 
Conclusions: These findings suggest that changes in endocannabinoid gradients due to altered 
tissue levels contribute to myeloid cell recruitment from the bone marrow to the infarcted heart, 
with crucial consequences on cardiac healing and function. 
 
Key words: myocardial infarction, monocytes, neutrophils, monoacylglycerol lipase, CB2 
cannabinoid receptor  
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1. Introduction 
The endocannabinoid system is a regulatory lipid signaling system that is involved in the 
homeostatic control of many physiological processes. These include the regulation of immune 
cell function, which is mainly attributed to cannabinoid receptor 2 (CB2) signaling.1 The most 
abundant endogenous CB2 agonist is 2-arachidonoylglycerol (2-AG), which is produced on 
demand from membrane phospholipids in many tissues, including bone marrow,2 spleen,3 blood 
and heart.4 The major biosynthesizing enzyme for 2-AG is diacylglycerol lipase (DAGL) and 
its metabolism to arachidonic acid and glycerol occurs through the catalytic activity of 
monoacylglycerol lipase (MAGL).5 CB2 deficiency in mice (CB2-/-) leads to exaggerated 
myocardial ischemia-reperfusion injury and unfavorable post-myocardial infarction (MI) 
healing.6-9 The beneficial effects of CB2 signaling in this setting involve cardioprotective 
mechanisms as well as anti-fibrotic and anti-inflammatory effects.6, 7, 10 CB2 is most abundantly 
expressed on immune cells, including myeloid cells.1 Stimulation of CB2 has been reported to 
regulate leukocyte recruitment, both directly via chemoattraction and indirectly through 
inhibition of chemokine-induced recruitment.11 Thus, CB2 signaling might play a dual role by 
either promoting local recruitment to inflammatory sites or by limiting immune cell recruitment 
and thus dampening an ongoing inflammatory response.  
MI leads to necrosis of a large number of cardiomyocytes, which induces a rapid infiltration of 
immune cells such as neutrophils and monocytes. Substantial progress has been made over the 
past few years in understanding their role in MI healing. These innate immune cells are 
instrumental in clearing the infarct area from tissue debris and subsequently promoting 
angiogenesis and fibrosis. The inflammatory response needs to be well-balanced, as an 
excessive number or a persistent presence of immune cells may lead to an unresolved resolution 
of inflammation. Consequently, the process of granulation tissue and collagen formation would 
be disturbed, which could promote cardiac dysfunction.12, 13 Conversely, in the case of 
insufficient numbers of immune cells, infarct healing is delayed because dead cells are not 
removed and repair processes not properly induced.12-14 Under homeostatic conditions, myeloid 
cells are produced and stored in the bone marrow and spleen, from where they are rapidly 
mobilized after an acute MI. In view of a potential role of endocannabinoid signaling in 
leukocyte retention in the bone marrow niche, 2-AG levels have been reported to be much 
higher in bone marrow and spleen compared to plasma, suggesting a homeostatic gradient.2 On 
the other hand, tissue injury leads to a significant increase in blood and organ endocannabinoid 
levels.15-17 
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Here, we studied the role of endocannabinoid 2-AG signaling in myeloid cell mobilization and 
recruitment during homeostasis and in response to cardiac injury in mice. Our data reveal that 
2-AG induces myeloid cell mobilization into the blood, which is blunted in absence of CB2. 
MI increases systemic and cardiac 2-AG levels by shifting the expression profile of 2-AG 
biosynthesizing and degrading enzymes between bone marrow and infarcted myocardium, 
thereby promoting a gradient favoring myeloid cell recruitment to the injured heart. Blocking 
of the MAGL pathway in mice subjected to MI increased cardiac myeloid cell infiltration and 
inflammation, leading to increased infarct sizes, impaired cardiac wound healing and worsened 
cardiac function. 
 
 
2. Methods 
2.1 Animal experiments 
Female 10- to 12-week-old C57BL/6J (wildtype, WT) and cannabinoid receptor (CB2-/-) 18 
mice (with constitutive knockout of the gene encoding CB2) were used in this study. Mice were 
bred and housed under controlled conditions in a 12 h light/12 h dark cycle. For leukocyte 
mobilization experiments under steady state, mice received intravenous injections of 10 mg/kg 
2-arachidonoylglycerol (Tocris).19 MI was induced by permanent ligation of the left anterior 
descending coronary artery (LAD). Selective experiments were performed in mice subjected to 
transient 45 min of myocardial ischemia followed by 24 h or 7 days of reperfusion. Sham-
operated animals were submitted to the same surgical protocol as described below but without 
LAD occlusion. Mice were first randomized and then underwent either sham- or I/R-surgeries 
on the same day alternating between both surgeries to prevent any procedural or time-of-surgery 
bias. Sham- and MI-operated mice were harvested together 24h after surgery and all subsequent 
experiments of both groups were performed together. For the MI surgeries, mice were 
anesthetized with midazolam (5 mg/kg), medetomidin (0,5 mg/kg) and fentanyl (0,05 mg/kg), 
intubated and ventilated with a MiniVent mouse ventilator (Harvard Apparatus, Holliston, 
MA). A left thoracotomy was performed in the 4th left intercostal space, and the pericardium 
was carefully incised to maintain the integrity of the pericardial adipose tissue. MI was induced 
by permanent or transient ligation of the LAD distal to its bifurcation from the main stem with 
monofilament nylon 7-0 sutures (Ethicon, Somerville, USA). The chest wall and skin were 
closed with 5-0 nylon sutures (Ethicon, Sommerville, NJ). After surgery, naloxone (1,2 mg/kg), 
flumazenil (0,5 mg/kg) and atipamezol (2,5 mg/kg) were injected to reverse the effect of 
anesthesia. Post-operative analgesia (buprenorphine; 0,1 mg/kg) was given for the first 12 h 
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after surgery. In selective experiments, mice received intraperitoneal injections of MAGL 
inhibitor JZL184 (16mg/kg; CAS 1101854-58-3; Cayman Chemical) or corresponding vehicle 
(5% DMSO in saline) one day before LAD ligation, followed by injections at day 1, 3, 5, 7, 9, 
11, 13, 15, 17, 19 and 21 after LAD occlusion (or until harvest). At the end of the experiment, 
mice were euthanized by intraperitoneal injection of anesthesia overdose (90 mg/kg ketamine, 
6 mg/kg xylazine) and subsequent exsanguination via cardiac puncture followed by perfusion 
with phosphate buffered saline. All animal experiments were approved by the local ethical 
committee and are in accordance with the guidelines from Directive 2010/63/EU of the 
European Parliament on the protection of animals used for scientific purposes. 
 
2.2 Echocardiography 
Transthoracic echocardiography was performed before and 3, 7, 14 and 21 days after MI on 
mildly anesthetized spontaneously breathing mice (sedated by inhalation of 1% isoflurane, 1 
L/min oxygen), using a Vevo 3100 High Resolution Imaging system (Visualsonics, Toronto, 
Canada). The mice were placed on a heated ECG platform and left parasternal long axis view 
and left mid-papillary short axis views were acquired in B-Mode and M-Mode, respectively. 
End-diastolic volumes, end-systolic volumes, stroke volumes, ejection fractions and fractional 
shortening were evaluated on the left parasternal long axis view. The left ventricular anterior 
wall thickness was measured on the left mid-papillary short axis view in systole and diastole 
and the average between heart cycles was calculated. Vector displacement and 3-D wall 
displacement were generated and cardiac output was calculated using the Vevo software. 
 
2.3 Infarct size and mortality 
Hearts were perfused and harvested 24 h after LAD ligation and sectioned into 4 equal 
transverse slices. The slices were incubated in 2% triphenyltetrazolium chloride (TTC) solution 
(Sigma-Aldrich) at 37°C for 15 min and fixed overnight in 4% formol at 4°C. Images were 
taken at 10x magnification, and quantification of viable (red) and infarct areas (white) was 
performed in a blinded manner with Image J software. Each mouse, which died after surgery 
prior to organ harvest underwent thoracotomy for post-mortem investigation if a cardiac rupture 
with intrapericardial hemorrhage had occurred. 
 
2.4 Histology  
Four-micrometer paraffin heart sections were stained with Masson’s trichrome as follows: 
sections were rehydrated and incubated in heated Boin’s solution before staining in Weigert’s 
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iron hematoxylin and Biebrich scarlet-acid fuchsin solution. After transferring to 
phosphotungstic/phosphomolybdic acid and subsequent staining with aniline blue, sections 
were dehydrated and mounted with Entellan® (Sigma-Aldrich). Fibrosis was quantified as the 
relative area of blue staining (collagen) compared to the left ventricle surface, as an average of 
3–4 sections per heart at the level of the papillary muscle, using ImageJ software.20 Remnants 
of pericardial tissue around the heart were excluded from fibrosis quantification. The anterior 
wall thickness of the left ventricle was measured on Masson’s trichome-stained sections as an 
average of 3–4 sections per heart. For Sirius Red staining of collagen, 3–4 sections per heart 
were incubated for 40 min with 0.1% Sirius Red (Sigma-Aldrich). Sections were photographed 
with identical exposure settings under ordinary polychromatic or polarized light microscopy. 
Interstitial collagen subtypes were evaluated using polarized light illumination; under this 
condition, thicker type I collagen fibers appeared orange or red, whereas thinner type III 
collagen fibers were yellow or green. TUNEL staining was performed with paraffin-embedded 
heart sections to evaluate apoptosis in the infarcted area according to the manufacturer’s 
instructions (DeadEnd™ Fluorometric TUNEL System, Promega). Sections were 
counterstained with DAPI (Fluoroshield mounting medium, Abcam) and mounted with cover 
slip. Images (10x magnification fields within infarct areas, 2-3 fields per section) were taken 
using a Leica DM6000 microscope and the analysis was performed using the Leica Application 
Suite LAS V4.3 software unless otherwise indicated. 
 
2.5 Cytokine and chemokine measurements 
Plasma chemokines and cytokines were measured with ProcartaPlexTM Multiplex immunoassay 
(eBioscience). Troponin I levels were measured with a precoated enzyme- linked 
immunosorbent assay (ELISA kit, CUSABIO). CXCL12 levels in bone marrow lavage of 
femurs (flushed with 1 ml PBS per femur) were determined with standard ELISA (Duoset, 
R&D Systems). Approximately 30 mg tissue dissected from infarct areas (apex region) were 
lysed in protein lysis buffer (50 mM Tris, 150 mM NaCl pH 8.0, 0.1% Triton X 100, 0.5% 
sodium deoxycholate, supplemented with protease inhibitor cocktail, Roche) using a tissue 
homogenizer (TissueLyser LT, Qiagen). Finally, cardiac chemokines were measured with 
standard ELISA kits (Duoset, R&D Systems) and protein concentrations in cardiac lysates were 
determined by Bradford Coomassie brilliant blue assay (Biorad).  
 
2.6 Blood Counter 
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Freshly obtained EDTA blood harvested by cardiac puncture was used to analyze leukocyte 
counts using an animal blood counter (scil Vet ABC Hematology Analyzer). 
 
2.7 Flow cytometry of heart and bone marrow 
Hearts were harvested, perfused with saline to remove peripheral cells, minced with fine 
scissors, and digested with collagenase I (450 U/ml), collagenase XI (125 U/ml), hyaluronidase 
type I-s (60 U/ml) and DNase (60 U/ml; Sigma-Aldrich and Worthington Biochemical 
Corporation) at 37°C for 1 h. Bone marrow cells were obtained by flushing femurs with 2 ml 
of saline and triturated through 70 μm nylon mesh strainer. The resulting single cell suspensions 
were centrifuged, resuspended in PBS supplemented with 1% BSA and CD16/CD32 Fc-block 
and incubated with following monoclonal antibodies for 30 min at 4°C at 1/1000 dilution: anti-
CD45.2 (clone 104, BD Biosciences), anti-CD11b (clone M1/70, BioLegend), anti-Ly6G 
(clone 1A8, BioLegend), anti-F4/80 (clone BM8, BioLegend), and isotype controls 
(BioLegend). Anti-CD115 (clone AFS98, BioLegend) and anti-CD206 (clone C068C2, 
BioLegend) were used at 1/500 dilution. Neutrophils were identified as CD45+, CD11b+, 
Ly6G+; blood monocytes as CD45+, CD11b+, Ly6G-, F4/80-, CD115+ and further gated for 
Ly6Chigh and Ly6Clow expressing subpopulations; cardiac monocytes as CD45+, CD11b+, 
Ly6G-, F4/80- and further gated for the Ly6Chigh expressing subpopulation (Supplemental 
Figure I); cardiac macrophages as CD45+, CD11b+, Ly6G-, F4/80+ and further gated for 
CD206- for M1 subpopulation and CD206+ for M2 subpopulation. Data were acquired on a 
FACS Canto II (BD Biosciences), and analysis was performed with FloJo software (Ashland, 
USA). 
 
2.8 Quantitative real time RT PCR 
Whole RNA from lysed hearts (TissueLyser LT, Qiagen) or bone marrow cells was extracted 
(peqGold Trifast and Total RNA kit, Peqlab) and reverse transcribed (PrimeScriptTM RT 
reagent kit, Clontech). Real-time PCR was performed with the 7900HT Sequence Detection 
System (Applied Biosystems) using the KAPA PROBE FAST Universal qPCR kit (Peqlab) 
unless otherwise indicated and predesigned primer and probe mix (DAGL-, 
Mm00523381_m1; Vcam1, Mm01320970_m1; TaqMan® Gene Expression Assays, Life 
Technologies) as well as custom primers and probes (Supplemental Table 1; Eurofins 
Genomics). Real time PCR analysis of Mmp9 was performed with SYBR Green Master Mix 
(Applied Biosystems) and custom primers (Supplemental Table 1). Messenger RNA expression 
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of markers of interest was normalized to hypoxanthine-guanine phosphoribosyltransferase 
(HPRT), and the fold induction was calculated by the comparative Ct method. 
 
2.9 Western Blotting 
The cardiac infarct area was excised and lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH 8.0) supplemented with a protease 
inhibitor cocktail (Complete Mini, Roche) using a tissue homogenizer (TissueLyser LT, 
Qiagen). Aliquots (30 μg) of total protein were separated by SDS-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. After blocking for 1 h in Tris-
buffered saline containing 0.1% Tween 20 and 5% skim milk (Carl Roth), membranes were 
probed overnight at 4°C with primary antibody against MMP-9 (R&D, MAB911; 1/2000 
dilution) or 60 min for GAPDH (Sigma-Aldrich, G954; 1/10000). Densitometric quantification 
of protein bands was performed using ImageJ software (NIH, Bethesda, MD, USA) and MMP9 
expression was normalized to GAPDH.  
 
2.10 Endocannabinoid tissue measurements  
Endocannabinoids were extracted from 100 μl of plasma or 10 mg cardiac tissue by liquid-
liquid extraction, and then separated by liquid chromatography (Ultimate 3000RS, Dionex, CA, 
USA). Analyses were performed on a 5500 QTrap® triple quadrupole/linear ion trap (QqQLIT) 
mass spectrometer equipped with a TurboIon-SprayTM interface (AB Sciex, Concord, ON, 
Canada).21, 22  
 
2.11 Statistical analysis 
Comparisons between two groups of normally distributed and not connected data were 
performed using the unpaired Student´s t-test. Comparisons between two groups of normally 
distributed and connected data were performed using the paired Student´s t-test. Comparisons 
between multiple group comparisons were performed by two-way ANOVA followed by 
Bonferroni post-hoc test. Mortality was analyzed by log-rank test. All data are expressed as 
mean ± SEM, and statistical analysis was performed with Prism Software (version 7; GraphPad, 
CA). P<0.05 was considered significant. 
 
 
3. Results 
3.1 Endocannabinoid 2-AG induces myeloid cell mobilization into the circulation 
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In order to test whether an increase in circulating endocannabinoid 2-AG levels might induce 
myeloid cell mobilization from hematopoietic reservoirs into the circulation, we injected a 
bolus of 2-AG (10 mg/kg) intravenously into WT mice. The comparison of blood counts before 
and 2 h after 2-AG administration in same animals revealed at least 2-fold higher circulating 
numbers of neutrophils and monocytes (both Ly6Chigh and Ly6Clow populations) after 2-AG 
injection (Figure 1). To clarify whether the release into the blood was mediated via CB2 
receptors, we repeated the same experiment in CB2-/- mice. In support of a crucial role for CB2 
signaling in myeloid cell mobilization, systemic 2-AG administration failed to increase 
monocyte counts and raised only 1.3-fold neutrophil counts in these mice (Figure 1). However, 
we noticed that circulating blood neutrophil counts per se were higher in CB2-/- compared to 
WT mice (WT 0,78 x 106/ml ± 0,08; CB2-/- 1,21 x 106/ml ± 0,11 at baseline; P < 0.05). We 
hypothesized that elevated blood neutrophil counts in CB2-/- mice at baseline might be a 
consequence of alterations in factors regulating homeostatic granulocyte retention in the bone 
marrow. Indeed, we found slightly lower neutrophil counts in the bone marrow of CB2-/- mice 
(Supplemental Figure IIA). This phenotype was accompanied by reduced bone marrow levels 
of CXCL12 (Supplemental Figure IIB), a chemokine released by stromal cells to retain 
neutrophil progenitors and mature neutrophils at their site of production. Moreover, we detected 
a 50% lower VCAM-1 mRNA expression in lysates of hematopoietic bone marrow cells 
obtained from CB2-/- compared to WT mice (Supplemental Figure IIC). Thus, reduced 
expression of VCAM-1, which binds to integrins expressed by neutrophils, might contribute to 
enhanced neutrophil egress from the bone marrow. 
 
3.2 MI induces an inverted expression profile of endocannabinoid synthesizing and 
metabolizing enzymes between bone marrow and heart 
To clarify whether endocannabinoid levels might be systemically induced after MI in our mouse 
model, we quantified various endocannabinoids and related lipid mediators in the plasma and 
myocardium of non-infarcted versus infarcted WT mice. We found that only 2-AG was 
upregulated in hearts and plasma 24 h after MI, while anandamide, palmitoylethanolamide and 
oleoylethanolamide were not changed (Figure 2A-B). We further compared tissue mRNA levels 
of enzymes involved in 2-AG biosynthesis and metabolism between steady state and 24 h after 
MI. Cardiac levels of endocannabinoid 2-AG producing enzyme DAGL- were 2-fold higher 
24 h after MI compared to baseline (Figure 2C), whereas its bone marrow expression levels 
decreased (Figure 2D). Conversely, mRNA levels of the enzyme MAGL which metabolizes 2-
AG were significantly downregulated in ischemic myocardium (Figure 2C), but massively 
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upregulated in the bone marrow (Figure 2D). Similar expression patterns were observed in 
CB2-/- mice (Supplemental Figure III). Thus, our data indicate that MI leads to an altered 2-
AG gradient between bone marrow, plasma and heart due to a modulation of tissue and plasma 
levels, which may promote leukocyte mobilization.  
 
3.3 Pharmacological blockade of 2-AG metabolism enhances cardiac neutrophil and 
monocyte recruitment and inflammation 
To further clarify the causal implication of 2-AG in post-MI myeloid cell recruitment, we 
treated mice with a pharmacological inhibitor of the 2-AG degrading enzyme MAGL (JZL184) 
or with the corresponding vehicle (DMSO) (Figure 3A). Blood counter analysis 24 h after MI 
revealed significantly higher circulating granulocyte and monocyte counts in mice receiving 
MAGL inhibitor compared to vehicle-treated mice (Figure 3B). The effect on cardiac myeloid 
cell infiltrates was even more impressive, revealing at least 2-fold higher cardiac neutrophil and 
inflammatory Ly6Chigh monocyte counts in JZL184- compared to vehicle-treated mice (Figure 
3C). Concomitantly, protein levels of neutrophil recruiting chemokines CXCL1 and CXCL2 
within the infarcted myocardium were significantly elevated in JZL184-treated mice 24 h after 
MI, while levels of monocyte recruiting chemokine CCL2 were not significantly different 
compared to the vehicle-treated mice (Figure 3D). Infiltrated neutrophils release their granule 
proteins such as MMP9, which may further contribute to cardiac tissue damage in addition to 
the primary ischemic event. In line with increased neutrophil counts in hearts of JZL184-treated 
mice, Western blot analysis confirmed significantly higher cardiac MMP9 protein levels at the 
same time point (Figure 3E-F). 
The increase in cardiac cytokine levels was accompanied by increased plasma levels of the 
inflammatory cytokine TNF in JZL184-treated mice 24 h after MI (Figure 3G), whereas 
CXCL1, CXCL2 and CCL2 plasma levels were not significantly higher (Figure 3H).  
 
3.4 Pharmacological MAGL-inhibition increases infarct size and mortality 
In agreement with enhanced inflammatory cell recruitment, mice receiving MAGL inhibitor 
had significantly larger infarct sizes quantified by TTC staining 24 h after permanent LAD 
occlusion (Figure 4A-B). Troponin I plasma levels 24 h after MI were not significantly different 
between both groups, possibly because this time point of analysis was beyond the plasma peak 
of this clinical marker (Figure 4C). Survival analysis after MI revealed a slightly higher 
mortality with increased incidences of ventricular ruptures in JZL184-treated mice compared 
with the vehicle group (Figure 4D-E). 
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3.5 Pharmacological MAGL-inhibition impairs ventricular remodeling 7d after MI 
To investigate the consequences of 2-AG driven inflammation on post-MI wound healing and 
remodeling, we subjected mice treated with either vehicle or MAGL inhibitor to permanent 
LAD ligation and performed analysis of hearts after 7 days. Immunhistological TUNEL 
staining and subsequent analysis of apoptotic cells within the infarct area showed no differences 
between vehicle- and JZL184-treated mice (Figure 5 A-B). To study the effect of JZL184 
treatment on cardiac fibrosis we performed Masson´s trichrome staining of infarcted hearts. 
JZL184-treated mice had larger ventricular scars with a significantly thinner left ventricular 
anterior wall thickness then vehicle-treated mice (Figure 5 C-D). Sirius red staining and 
subsequent analysis of the collagen composition within in the infarcted myocardium revealed a 
significantly lower density of thick collagen type I fibers in JZL184-treated mice compared to 
the vehicle group (Figure 5 E-F). Larger fibrotic scars and less collagen type 1 fibers might be 
contributing factors for the higher incidence of ventricular ruptures in the JZL184-treated mice. 
 
3.6 Pharmacological MAGL-inhibition worsens cardiac function after MI 
Since enhanced inflammation and impaired wound healing may have detrimental effects on 
post-MI outcome, we performed additional experiments to study prolonged effects of MAGL 
inhibition on cardiac function parameters. Echocardiographic analysis of vector displacement 
of ventricular walls, which indicates ventricular wall movement, appeared more reduced in 
JZL184-treated mice 14 days after MI (Figure 6A). The quantification of echocardiographic 
measurements revealed massively reduced ejection fractions 3 to 21 days post-MI in both 
experimental groups, with a significantly more pronounced decline in JZL184-treated mice 
(Figure 6B). In parallel, there was a continuous increase of the end-systolic and end-diastolic 
volumes, which was significantly more pronounced in JZL184-treated mice 14 and 21 days 
after MI compared to the vehicle group (Figure 6B). Stroke volumes and cardiac output 
declined to a similar extend in both groups after MI (Figure 6B). Heart rates after MI did not 
differ between both groups (Supplemental Figure IVB). Measurements of the left ventricular 
anterior wall thickness revealed thinner walls in the JZL184-treated mice, thereby confirming 
our histological findings (Supplemental Figure IVC). 
 
3.7 Pharmacological MAGL inhibition after ischemia-reperfusion increases cardiac 
myeloid cell recruitment, M1 macrophage accumulation and ventricular fibrosis  
Finally, we aimed to validate the effect of MAGL inhibition in a clinically more relevant 
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scenario and subjected mice to transient LAD occlusion with 45 min of ischemia and 
subsequent reperfusion or to corresponding sham operations (Figure 7A). Similar to the effects 
observed in the permanent occlusion model, JZL184 treatment resulted in higher numbers of 
neutrophils and Ly6Chigh monocytes recruited to the heart 24 h after ischemia-reperfusion, while 
sham surgery did not or only minimally induce recruitment of these inflammatory myeloid cell 
subsets into the myocardium (Figure 7B). Concomitantly, plasma levels of neutrophil recruiting 
chemokine CXCL1 were significantly elevated in JZL184-treated mice compared to vehicle-
treated mice 24 h after I/R (Figure 7C). In line with a more pronounced inflammatory response 
in these mice, cardiac MMP9 mRNA levels were also more increased at the same time point, 
whereas sham surgery resulted only in a minor increase of cardiac MMP9 mRNA levels (Figure 
7D). Beyond the acute inflammatory phase 7 days after ischemia-reperfusion, we detected 
significantly more macrophages, in particular of the inflammatory M1 subset, in the 
myocardium of JZL184-treated mice (Figure 7E-F). Moreover, histological analysis of 
infarcted hearts 7 days after ischemia-reperfusion revealed larger ventricular scar sizes in 
JZL184-treated mice (Figure 7G-H), which is in agreement with our findings in the permanent 
LAD occlusion model. 
 
 
4. Discussion 
Over the past few years, the bone marrow has gained increasing interest as a source of myeloid 
cells, which infiltrate the heart after an acute MI. Under steady state, a large pool of leukocytes 
is stored in the bone marrow and supplies blood leukocytes at low numbers to self-maintain 
their numbers in the circulation. Acute MI alters this leukocyte supply chain, leading to 
leukocytosis and a massive infiltration of myeloid cells into the injured myocardium.23 
Damage-associated molecular patterns derived from dying cells likely contribute to the 
acceleration of hematopoiesis to meet the high demand of immune cells, which are required for 
initiating cardiac repair.24 Here, we identified the endocannabinoid 2-AG/CB2 axis as a crucial 
modulator of myeloid cell release and cardiac recruitment after MI. 
In support of a role for CB2 signaling in regulating bone marrow retention of neutrophils during 
steady state, we report that mice lacking CB2 have significantly lower bone marrow CXCL12 
and VCAM-1 expression levels. CXCL12 released by bone marrow stromal cells is an 
important retention factor for immature neutrophils expressing its cognate receptor CXCR4.25, 
26 VCAM-1 in the bone marrow is expressed by stromal and endothelial cells as well as some 
hematopoietic cells such as macrophages.27 Its major ligand is the integrin very late antigen 4 
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(VLA-4; α4β1) which is expressed by neutrophils.28 Thus, reduced CXCL12 and VCAM-1 
expression might both contribute to enhanced neutrophil egress from the bone marrow in 
absence of CB2 signaling. In line with the role of CB2 in regulating myeloid cell mobilization 
from the bone marrow, systemic endocannabinoid administration into CB2-/- mice had only 
little effects on myeloid cell mobilization into the circulation, whereas 2-AG induced myeloid 
cell release was very pronounced in WT mice.  
During steady state, we found that leukocyte retention in the bone marrow is supported by high 
expression levels of endocannabinoid 2-AG synthesizing enzyme DAGL and low levels of its 
metabolizing enzyme MAGL. After MI, a dramatic change in the bone marrow expression of 
these enzymes occurs and in parallel 2-AG plasma levels increase, which are likely to contribute 
to the release of myeloid cells into the blood. In line with a previous report in an experimental 
model of liver injury,29 we also observed an altered expression of endocannabinoid synthesizing 
and metabolizing enzymes as well as increased 2-AG levels in the injured myocardium 24 h 
after MI. This might be a direct effect of locally released inflammatory factors in the injured 
tissue.30 Strikingly, the alterations in enzyme expression levels are much more important in the 
bone marrow compared to the ischemic myocardium. Although elevations of various 
endocannabinoids including anandamide have been reported in cardiovascular diseases,15, 31 we 
found that only 2-AG levels increased in the plasma and myocardium after acute MI. The MI-
induced changes in the expression of endocannabinoid 2-AG synthesizing and metabolizing 
enzymes were comparable in both WT and CB2-/- mice. Given that global CB2 deficiency per 
se has multiple effects on cardiac healing responses,6-9 we subsequently focused only on WT 
mice to study the consequences of pharmacological MAGL inhibition on acute post-MI 
inflammation and healing. 
After MI, increased sympathetic nervous system activity triggers hematopoietic stem and 
progenitor proliferation in the bone marrow and their release into the circulation.32 Moreover, 
danger signals released from ischemic myocardium into the circulation might contribute to an 
activation of the hematopoietic bone marrow niche.33 Possibly these factors are also involved 
in the modulation of endocannabinoid enzyme expression and consequently endocannabinoid 
gradients between bone marrow, circulation and hearts. We provided two different 
experimental proofs that enhanced circulating endocannabinoid levels mediate myeloid cell 
mobilization in WT mice. First, at steady state systemic administration of 2-AG resulted in 
rapid increases of circulating leukocyte counts. Second, pharmacological inhibition of 2-AG 
metabolizing enzyme MAGL further upregulated MI-induced neutrophil and monocyte 
mobilization into the blood and their recruitment to the ischemic heart. We validated that 
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pharmacological MAGL inhibition at steady state resulted in approximately two-fold increased 
plasma 2-AG levels (data not shown), which are approximately in the range of the levels we 
found 24 h after MI. Several mechanisms might contribute to the enhanced cardiac leukocyte 
recruitment after injection of the MAGL inhibitor. Elevated systemic 2-AG levels might 
enhance myeloid cell mobilization from the bone marrow through a chemotactic effect, leading 
to increased cardiac recruitment.11 Alternatively, 2-AG might promote inflammatory cytokine 
release in the heart as we found higher concentrations of neutrophil-recruiting CXCL1 and 
CXCL2 within the infarcted myocardium in MAGL inhibitor-treated mice.34-36 However, this 
could also be a secondary consequence of enhanced neutrophil recruitment by 2-AG-mediated 
chemoattraction. 
The increased neutrophil and monocyte-driven inflammation and MMP9 release in response to 
MAGL inhibition during the early phase after MI translated into a massive infarct. In the later 
infarct healing phase 7 days after ischemia-reperfusion, MAGL inhibition led to increased 
numbers of cardiac macrophages of an inflammatory phenotype, which might be a consequence 
of the enhanced monocyte recruitment or a delay in inflammation resolution.37 These cells are 
likely to contribute to an unfavorable cardiac wound healing, as observed in mice treated with 
JZL184. Interestingly, MAGL inhibition did not affect apoptotic cell numbers in the infarct, 
which could indicate that phagocytosis function, mainly promoted by M2 macrophages, is 
unaffected by 2-AG. The increased cardiac MMP9 protein levels in mice treated with MAGL 
inhibitor, associated with larger ventricular scar sizes of a poor quality, are in line with previous 
reports that MMP9 regulates pathologic cardiac remodeling processes.38, 39 In particular, 
reduced density of collagen type I fibers and a thinner left ventricular anterior wall thickness in 
MAGL inhibitor-treated mice results in fragile ventricular walls, which bear the risk of cardiac 
ruptures.40, 41 This is in line with the higher mortality and increased incidence of cardiac rupture 
in mice receiving MAGL inhibitor compared to the vehicle group. The observation that 
excessive cardiac neutrophil infiltration into the heart of MAGL inhibitor-treated mice leads to 
an increased infarct size, cardiac rupture and worsened cardiac function is also in agreement 
with our previously published findings that time-of-day-dependent fluctuations of circulating 
blood and tissue neutrophil counts critically affect MI healing responses.40 Although 
endocannabinoid signaling per se might affect cardiovascular physiology,42 MAGL inhibition 
did not affect heart rate and cardiac output after MI. However, MAGL inhibitor-treated mice 
suffered from more pronounced decline of ejection fractions 3 to 21 days after MI and 
ventricular dilatation 14 to 21 days post-MI compared to the vehicle group. 
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Since timely revascularization is the gold standard of MI treatment, we aimed to verify our 
finding in a clinically more relevant myocardial ischemia-reperfusion MI model. This model 
differs from the permanent ligation MI model as revascularization after ischemia results in 
reperfusion injury, which originates, among other, from a massive leukocyte infiltration 
immediately after reopening coronary blood flow.43 Similar to our findings in the permanent 
ligation model, MAGL inhibition after ischemia-reperfusion increased cardiac myeloid 
recruitment, which was accompanied by elevated plasma CXCL1 and cardiac MMP9 mRNA 
levels in the early inflammatory phase. Beyond the acute inflammatory phase, we noted a 
sustained presence of proinflammatory M1 macrophages in the myocardium and larger 
ventricular scar sizes. Although these preclinical observations need to be confirmed in larger 
animal models or clinical trials, our findings should raise awareness for the potential role of 
endocannabinoids in contributing to post-MI inflammation and outcome. 
Finally, it has to be considered that we performed this study only in female mice, because male 
mice in experimental MI models have a higher incidence of mortality due to cardiac rupture. 
The underlying cause for this gender difference in cardiac rupture involves higher severity of 
inflammation, MMP activation and damage to collagen matrix in males compared to females.44 
We believe that the use of female mice with a more moderate post-MI inflammatory response, 
lower incidence of mortality and thus lower number of mice to be used is more suitable for 
studying the causal implication of the 2AG/CB2 axis in this experimental model in accordance 
with the 3R guidelines. Nevertheless, it is certainly of crucial importance to consider gender 
differences when interpreting experimental and clinical data. 
To conclude, our findings suggest that alterations of endocannabinoid 2-AG signaling via CB2 
cannabinoid receptors affect leukocyte counts at steady state and after myocardial infarction, 
which is of clinical importance as neutrophilia after myocardial infarction is associated with a 
higher mortality and a poorer outcome.45, 46 While various side effects of pharmaceutical drugs 
interfering with the endocannabinoid system have been reported, little is known about the effect 
of these drugs on the inflammatory system. Our work raises the concern that plant-derived or 
synthetic cannabinoids might affect leukocyte counts in patients with cardiovascular diseases 
thereby increasing their risk for adverse events and outcomes. Given the increasing 
consumption of plant derived and synthetic cannabinoids and the use of cannabinoids for a 
limited number of therapeutic applications, there is certainly a high interest for further 
investigations in this field. 
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Figure legends 
 
Figure 1. The endocannabinoid 2-AG/CB2 receptor axis promotes leukocyte mobilization. A, 
Representative flow cytometry plots and (B) blood counts of WT and CB2-/- mice before and 
2 h after intravenous (i.v.) 2-AG bolus injections. Symbols indicate individual mice (n = 6); 
paired student's t-test; *P<0.05; ns, not significant. 
 
Figure 2. MI inverts bone marrow and cardiac expression profiles of endocannabinoid 
biosynthesis and degradation pathways. Levels of anandamide (AEA), palmitoylethanolamide 
(PEA), oleoylethanolamine (OEA), and 2-arachidonoylglycerol (2-AG) in plasma (A) and heart 
(B) at steady state and 24 h after MI in WT mice. Messenger RNA levels of endocannabinoid 
synthesizing enzyme DAGL and metabolizing enzyme MAGL in heart (C) and bone marrow 
(D) at steady state and 24 h after MI in WT mice. Enzyme mRNA levels were normalized to 
HPRT and the fold change after MI compared to baseline (no MI) was calculated for each 
genotype. All data are mean ± SEM (n = 6-10 mice); two-way ANOVA followed by Bonferroni 
post hoc test (A-C) or unpaired student's t-test (D-E); *P<0.05; ns, not significant.  
 
Figure 3. Pharmacological MAGL inhibition enhances cardiac leukocyte recruitment and 
inflammation after MI. A, Permanent LAD occlusion was performed in WT mice receiving 
intraperitoneal injection of vehicle (DMSO) or MAGL inhibitor (JZL184) 24 h before surgery. 
B, Blood counts of granulocytes and monocytes 24 h after MI (n = 9-11). C, Flow cytometric 
quantification of neutrophils and Ly6Chigh monocytes in digested hearts 24 h after MI (n = 6). 
D, Protein levels of pro-inflammatory chemokines within the infarcted myocardium 24 h after 
MI (n = 8-9 mice). E-F, Western blot analysis of cardiac MMP9 (active form) and GAPDH 24 
h after MI and quantification of MMP9 band density, normalized to GAPDH and shown as 
arbitrary units (a.u.) relative to the vehicle group (set to 100; n = 7-8 mice). G-H, Plasma levels 
of pro-inflammatory cytokines (n = 5-7) and chemokines 24 h after MI (n = 6-7 mice). Data 
were obtained in two independent experiments. All data are mean ± SEM; unpaired student's t-
test; *P<0.05. 
 
Figure 4. Pharmacological MAGL inhibition increases infarct size and mortality. A, Permanent 
LAD occlusion was performed in WT mice receiving either vehicle (DMSO) or MAGL 
inhibitor (JZL184) intraperitoneally 24 h before and subsequently every 48 h until harvest. B, 
TTC staining (yellow, infarct; red, vital myocardium) and quantification of infarct size 
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normalized to the left ventricle (LV; n = 6-8 mice). C, Plasma troponin I levels 24 h after MI 
(n = 19 mice). B-C, Data are mean ± SEM; unpaired student's t-test. D, Survival rates after MI 
(total n = 68 mice) and (E) cause of death. Statistical significance was determined using a log-
rank test. All data were obtained in at least two independent experiments; *P<0.05.  
 
Figure 5. Pharmacological MAGL inhibition impairs ventricular remodeling 7d after MI. 
Permanent LAD occlusion was performed in WT mice receiving either vehicle (DMSO) or 
MAGL inhibitor (JZL184) intraperitoneally 24 h before and subsequently every 48 h until 
harvest. A, Representative TUNEL staining of the infarcted myocardium of DMSO- and 
JZL184-treated mice 7 days after myocardial infarction (blue, nuclei; green, TUNEL; 10x 
magnification; scale bars represent 800 μm). B, Quantification of TUNEL-positive area within 
the infarcted area. C, Masson’s trichrome staining of fibrosis (blue, collagen; red, vital 
myocardium; 20x magnification; scale bars represent 80 μm). D, Quantification of fibrotic scar 
size relative to total left ventricular (LV) area and quantification of the LV anterior wall 
thickness of the fibrotic scar. E, Representative bright field (left) and corresponding polarized 
light images (right) of Sirius-Red staining identifying collagen type I fibers as red-yellow fibers 
and collagen type III fibers as green fibers within the infarct area (20x magnification; scale bars 
represent 80 μm). F, Quantification of collagen type I positive area and collagen type III positive 
area within the infarcted area. Data were obtained in two independent experiments (n = 6-9 
mice in total). All data are mean ± SEM; unpaired student's t-test; *P<0.05.  
 
Figure 6. Pharmacological MAGL-inhibition worsens cardiac function after MI. Permanent 
LAD occlusion was performed in WT mice receiving either vehicle (DMSO) or MAGL 
inhibitor (JZL184) intraperitoneally 24 h before and subsequently every 48 h until harvest. A, 
Representative vector diagrams showing the direction and magnitude of myocardial contraction 
at midsystole. Representative three-dimensional regional wall displacement illustrations 
showing contraction (positive values, yellow–red) or relaxation (negative values, blue) of 
consecutive cardiac cycle results. B, Echocardiographic assessment of cardiac function 
parameters and left ventricular diameters after MI. Data were obtained in three independent 
experiments (n = 12-15 mice in total). All data are mean ± SEM; two-way ANOVA followed 
by Bonferroni post hoc test; *P<0.05.  
 
Figure 7. Pharmacological MAGL inhibition increases cardiac myeloid cell recruitment 
and ventricular fibrosis after myocardial ischemia-reperfusion. A, 45 minutes of 
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myocardial ischemia followed by reperfusion or corresponding sham operations were 
performed in WT mice receiving either vehicle (DMSO) or MAGL inhibitor (JZL184) 
intraperitoneally 24 h before and subsequently every 48 h until harvest. B, Flow cytometric 
quantification of neutrophils and Ly6Chigh monocytes in digested hearts 24 h after ischemia-
reperfusion or sham operation (n = 6 -13 mice). C, Plasma levels of the pro-inflammatory 
cytokine CXCL1 24 h after I/R (n = 6 mice). D, MMP9 mRNA expression within the infarcted 
myocardium 24 h after ischemia-reperfusion or the corresponding myocardium of sham 
operated mice normalized to HPRT and shown as fold change to steady state myocardium (The 
dotted line indicates steady state levels ;n = 6 mice). E, Flow cytometric quantification of 
macrophages in digested hearts 7 days after ischemia-reperfusion (n = 6 mice). F, Pie chart of 
the ratio between inflammatory macrophages (M1 MΦ; CD206-) and reparative macrophages 
(M2 MΦ; CD206+) 7 days after ischemia-reperfusion (n = 6 mice). G, Representative images 
7 days after ischemia-reperfusion stained with Masson trichrome (blue, collagen; red, vital 
myocardium; 20x magnification; scale bars represent 50 µm). H, Quantification of fibrotic scar 
size relative to total left ventricular (LV) area 7 days after ischemia-reperfusion (n = 6 mice). 
Data were obtained in two independent experiments. All data are mean ± SEM; unpaired 
student's t-test; *P<0.05; two-way ANOVA followed by Bonferroni post hoc test (B, D) or 
unpaired student's t-test (C, E, F, H); *P<0.05; ns, not significant. 
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